Duncan
235241

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 13:23:09 ON 03 JUN 94
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 1994 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:  27 MAY 94   HIGHEST RN 155417-12-2
DICTIONARY FILE UPDATES: 03 JUN 94   HIGHEST RN 155417-12-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 1994

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

=> e factor viii/cn
E1            1     FACTOR VI/CN
E2            1     FACTOR VI (VITAMIN B12 ANALOG)/CN
E3            3 --> FACTOR VIII/CN
E4            1     FACTOR X/CN
E5            1     FACTOR XA/CN
E6            1     FACTOR XA-1/CN
E7            1     FACTOR XIIA/CN
E8            1     FACTOR XIII/CN
E9            1     FACTOR420 HYDROGENASE/CN
E10           1     FACTORATE/CN
E11           1     FACTREL/CN
E12           1     FACTUMYCIN/CN

=> s e3
L1            3 "FACTOR VIII"/CN

=> e f viii c/cn
E1            1     F RESIN/CN
E2            2     F STEEL/CN
E3            0 --> F VIII C/CN
E4            1     F-0000/CN
E5            1     F-0000-10/CN
E6            1     F-0000-20/CN
E7            1     F-0000-P-SULFURIZED/CN
E8            1     F-0008-P/CN
E9            1     F-0008-P-SULFURIZED/CN
E10           1     F-0208/CN
E11           2     F-10/CN
E12           1     F-102 GAS/CN

=> fil ca
FILE 'CA' ENTERED AT 13:24:01 ON 03 JUN 94
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 1994 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1967 - 28 May 1994 (940528/ED)  VOL 120 ISS 22

  To help control your online searching costs, consider using the
  HCA File when conducting SmartSELECT searches with large
```

numbers of terms.

```
=> s (l1 or ((factor or f)(w)viii(w)c)/ia)
          3765 L1
        138676 FACTOR/BI
        271357 FACTOR/AB
        322065 FACTOR/IA
                 (FACTOR/BI,AB)
         36612 F/BI
        235833 F/AB
        252964 F/IA
                 (F/BI,AB)
         17541 VIII/BI
         16019 VIII/AB
         29306 VIII/IA
                 (VIII/BI,AB)
        174863 C/BI
       1081855 C/AB
       1147451 C/IA
                 (C/BI,AB)
           200 ((FACTOR OR F)(W)VIII(W)C)/IA
L2         3786 (L1 OR ((FACTOR OR F)(W)VIII(W)C)/IA)

=> s l2 and (organic polymer or detergent)/ia
        129084 ORGANIC/BI
          1570 ORGANIC/AB
        130294 ORGANIC/IA
                 (ORGANIC/BI,AB)
        322038 POLYMER/BI
        244540 POLYMER/AB
        447877 POLYMER/IA
                 (POLYMER/BI,AB)
           508 ORGANIC POLYMER/IA
                 ((ORGANIC(W)POLYMER)/IA)
         21540 DETERGENT/BI
         30510 DETERGENT/AB
         40407 DETERGENT/IA
                 (DETERGENT/BI,AB)
L3           36 L2 AND (ORGANIC POLYMER OR DETERGENT)/IA

=> s l3 and plasma/ia
        242303 PLASMA/BI
        331095 PLASMA/AB
        382764 PLASMA/IA
                 (PLASMA/BI,AB)
L4           23 L3 AND PLASMA/IA

=> s l4 and (stabil? or stabl? or buffer?)/ia
        207232 STABIL?/BI
        353700 STABIL?/AB
        435736 STABIL?/IA
                 (STABIL?/BI,AB)
         40422 STABL?/BI
```

```
        235041 STABL?/AB
        256929 STABL?/IA
                 (STABL?/BI,AB)
         13484 BUFFER?/BI
        115884 BUFFER?/AB
        118760 BUFFER?/IA
                 (BUFFER?/BI,AB)
L5           3 L4 AND (STABIL? OR STABL? OR BUFFER?)/IA

=> d 1-3 .mh;s l4 not l5

L5   ANSWER 1 OF 3  CA  COPYRIGHT 1994 ACS
TI   Preparation of intermediate-purity factor VIII concentrate
by direct
     gel filtration of cryoprecipitate
SO   Vox Sang., 65(4), 251-7
AU   Teh, L. C.
PY   1993
AN   CA120(22):279944a  CA
AB   The authors report a new method to produce a solvent/
   detergent-treated and severe dry heat-treated factor VIII
     (FVIII) conc. (3-6 IU FVIII:C/mg protein). This method,
which uses a
     single purifn. step after cryopptn., is suitable for
scale-up to
     prodn. levels. FVIII was obtained from solvent/detergent
     -treated cryoppt. by a single gel filtration step using
Sephacryl
     S-400HR. The freeze-dried product was stable to heating at
     80.degree. for 72 h. The yield of the solvent/detergent
     and severe dry heat-treated product was 230 IU FVIII:C/kg
   plasma. The reconstituted product gave a 10% loss in FVIII:C
     activity after heating at 37.degree. for 6 h. The
feasibility of
     this method suggests that gel filtration using S-400HR can
be used
     solely or as part of a purifn. process for the prepn. of
high-purity
     FVIII concs.

L5   ANSWER 2 OF 3  CA  COPYRIGHT 1994 ACS
TI   Large-scale preparation of a highly purified solvent-
   detergent treated factor VIII concentrate
SO   Vox Sang., 60(3), 141-7
AU   Myers, Robert; Wickerhauser, Milan; Charamella, Leigh;
Simon,
     Louise; Nummy, William; Brodniewicz-Proba, Teresa
PY   1991
AN   CA115(4):35559j  CA
AB   Large-scale adaptation of a recently reported glycine pptn.
method
     for the prodn. of factor VIII (FVIII) conc. is described.
Scaling up
```

of the method required some modification including the addn. of Al(OH)3 to the glycine **buffer** to reduce the level of contaminating proteins in the final prepn. and the use of centrifugation to replace filtration by glass beads. Furthermore, the resultant product was virus inactivated by incorporation of the org. solvent and **detergent** technique. At industrial level, the modified method gave a good recovery of FVIII activity (230 IU/L **plasma**) with high purity (4 IU/mg protein). The final product, after virus inactivation and lyophilization, yielded 185 IU of FVIII activity per L of starting **plasma** and was considered to be suitable for clin. evaluation.

L5 ANSWER 3 OF 3 CA COPYRIGHT 1994 ACS
TI Progress in purification of virus-inactivated factor VIII concentrates. Three generations of solvent/**detergent** treated **plasma** derivatives
SO Arzneim.-Forsch., 39(10), 1302-5
AU Schwinn, H.; Smith, A.; Wolter, D.
PY 1989
AN CA112(2):11823c CA
AB A prodn. process of a newly developed highly purified and virus-inactivated Factor (F) VIII-conc. (Octa V.I. and Octavi) is presented. Taking advantage of a selective resin matrix and the solvent/**detergent** procedure for virus inactivation - known not to denaturate proteins - a product of a specific activity .gtoreq. 100 IU F VIII/mg was developed in the final container without the use of an immuno-affinity adsorption step. The main steps of the procedure are: pooled cryoppt. is extd., the ext. is cleared from fibrinogen at + 10.degree. and virus-inactivated at + 28.degree. after addn. of tri-Bu phosphate (TNBP) and **detergent**. Thereafter the ext. is brought in contact to a F VIII-selective anion exchange resin using a chromatog. column. TNBP and the **detergent** are removed by an extensive washing process and the F VIII-activity is concd. in a fraction, ready for filling, by means of a cascade of washing- and elution-**buffers**. The product is free from coagulate protein and .gamma.-globulins. The F VIIIC: Ag/**F VIII**: **C**-ratio is about unity, suggesting the F VIII-mol. remained in its native state. The development of highly purified F VIII conc.

```
     is based on 2 previous products of lesser purity (specific
activity
     of about 1 and 10 IU/mg). The evolution is shown by a
comparison of
     detailed anal. data.


L6          20 L4 NOT L5

=> s l6 and (amino acid or (arginine and glycine) or (arg and
gly))/ia
         263254 AMINO/BI
         307723 AMINO/AB
         418448 AMINO/IA
                  (AMINO/BI,AB)
        1171914 ACID/BI
        1113516 ACID/AB
        1705208 ACID/IA
                  (ACID/BI,AB)
         212257 AMINO ACID/IA
                  ((AMINO(W)ACID)/IA)
          19216 ARGININE/BI
          35317 ARGININE/AB
          42730 ARGININE/IA
                  (ARGININE/BI,AB)
          30514 GLYCINE/BI
          41491 GLYCINE/AB
          58773 GLYCINE/IA
                  (GLYCINE/BI,AB)
           1321 ARG/BI
          13648 ARG/AB
          14124 ARG/IA
                  (ARG/BI,AB)
           1741 GLY/BI
          20154 GLY/AB
          20723 GLY/IA
                  (GLY/BI,AB)
L7             0 L6 AND (AMINO ACID OR (ARGININE AND GLYCINE) OR
(ARG AND G
                 LY))/IA

=> s l6 and carbohydrate?/ia
          64782 CARBOHYDRATE?/BI
          53978 CARBOHYDRATE?/AB
          91612 CARBOHYDRATE?/IA
                  (CARBOHYDRATE?/BI,AB)
L8             0 L6 AND CARBOHYDRATE?/IA

=> dis his

     (FILE 'HOME' ENTERED AT 13:21:56 ON 03 JUN 94)
               SET PAGELENGTH SCROLL
```

```
     FILE 'REGISTRY' ENTERED AT 13:23:09 ON 03 JUN 94
                E FACTOR VIII/CN
L1            3 S E3
                E F VIII C/CN

     FILE 'CA' ENTERED AT 13:24:01 ON 03 JUN 94
L2         3786 S (L1 OR ((FACTOR OR F)(W)VIII(W)C)/IA)
L3           36 S L2 AND (ORGANIC POLYMER OR DETERGENT)/IA
L4           23 S L3 AND PLASMA/IA
L5            3 S L4 AND (STABIL? OR STABL? OR BUFFER?)/IA
L6           20 S L4 NOT L5
L7            0 S L6 AND (AMINO ACID OR (ARGININE AND GLYCINE)
OR (ARG AN
L8            0 S L6 AND CARBOHYDRATE?/IA

=> s (((factor or f)(w)viii(w)c)/ia)
        138676 FACTOR/BI
        271357 FACTOR/AB
        322065 FACTOR/IA
                 (FACTOR/BI,AB)
         36612 F/BI
        235833 F/AB
        252964 F/IA
                 (F/BI,AB)
         17541 VIII/BI
         16019 VIII/AB
         29306 VIII/IA
                 (VIII/BI,AB)
        174863 C/BI
       1081855 C/AB
       1147451 C/IA
                 (C/BI,AB)
L9          200 (((FACTOR OR F)(W)VIII(W)C)/IA)

=> s l9 and (prepar? or prepn)/ia
        832815 PREPAR?/BI
         22731 PREPAR?/AB
        851018 PREPAR?/IA
                 (PREPAR?/BI,AB)
       1239267 PREPN/BI
        228922 PREPN/AB
       1382810 PREPN/IA
                 (PREPN/BI,AB)
L10          46 L9 AND (PREPAR? OR PREPN)/IA

=> s l10 not l5
L11          45 L10 NOT L5

=> d 1-45 an ti so au pi ai py;s l6 not l11

L11  ANSWER 1 OF 45  CA  COPYRIGHT 1994 ACS
AN   CA120(18):226634t  CA
TI   Characterization of factors affecting the stability of
frozen
```

heparinized plasma
SO Vox Sang., 65(4), 258-70
AU Palmer, D. S.; Rosborough, D.; Perkins, H.; Bolton, T.; Rock, G.;
Ganz, P. R.
PY 1993

L11 ANSWER 2 OF 45 CA COPYRIGHT 1994 ACS
AN CA120(13):157515r CA
TI Purification of Factor VIII complex from serum
SO PCT Int. Appl., 34 pp.
IN Bhattacharya, Prabir; Motokubotta, Toshiharu
PI WO 9322337 A1 931111
AI WO 93-US4058 930430
PY 1993

L11 ANSWER 3 OF 45 CA COPYRIGHT 1994 ACS
AN CA120(5):52855y CA
TI Egg yolk fraction for increasing recombinant protein production in
mammalian cell culture
SO PCT Int. Appl., 20 pp.
IN Kongerslev, Leif; Pedersen, John
PI WO 9322425 A1 931111
AI WO 93-DK138 930423
PY 1993

L11 ANSWER 4 OF 45 CA COPYRIGHT 1994 ACS
AN CA119(8):80196g CA
TI Process for purifying Factor VIII, and **preparations** so obtained
SO Eur. Pat. Appl., 7 pp.
IN Grandgeorge, Michel; Lutsch, Charles
PI EP 534812 A1 930331
AI EP 92-402378 920901
PY 1993

L11 ANSWER 5 OF 45 CA COPYRIGHT 1994 ACS
AN CA118(20):197865v CA
TI **Factor VIII:c** concentrate virus inactivated: Progress in purification by using classic chromatographic methods
SO Vox Sang., 64(1), 13-18
AU Arrigi, Silvana; Pacenti, Lorenzo; Borri, Maria Giuseppina
PY 1993

L11 ANSWER 6 OF 45 CA COPYRIGHT 1994 ACS
AN CA117(6):55742h CA
TI Factor VIII yields from anticoagulant exchanged Haemonetics Ultralite plasma
SO Dev. Hematol. Immunol., 26(Coagulation Blood Transfus.), 49-54
AU Speak, J.; Cumming, A. M.; Wensley, R. T.

PY 1991

L11 ANSWER 7 OF 45 CA COPYRIGHT 1994 ACS
AN CA116(8):67159r CA
TI Method for **preparing** high-purity factor VIII including a rapid immunoadsorption step
SO PCT Int. Appl., 27 pp.
IN Chtourou, Abdessatar
PI WO 9118017 A1 911128
AI WO 91-FR400 910517
PY 1991

L11 ANSWER 8 OF 45 CA COPYRIGHT 1994 ACS
AN CA114(22):214230w CA
TI Further evidence that the residual vWf:Ag in porcine FVIII:C induces human platelet aggregation
SO Haemostasis, 20(5), 289-95
AU Saniabadi, A. R.; Marney, Y.; Belch, J. J. F.; Lowe, G. D. O.; Barbenel, J. C.; Madhok, R.; Forbes, C. D.
PY 1990

L11 ANSWER 9 OF 45 CA COPYRIGHT 1994 ACS
AN CA111(22):201439j CA
TI Inactivation and removal of human immunodeficiency virus in monoclonal-purified antihemophilic factor (human) (Humofil)
SO Thromb. Res., 55(5), 627-34
AU Piszkiewicz, Dennis; Sun, Chong Son; Tondreau, Sue C.
PY 1989

L11 ANSWER 10 OF 45 CA COPYRIGHT 1994 ACS
AN CA111(22):201435e CA
TI Severely heated therapeutic factor VIII concentrate of high specific activity
SO Vox Sang., 57(2), 97-103
AU Winkelman, L.; Owen, N. E.; Evans, D. R.; Evans, H.; Haddon, M. E.; Smith, J. K.; Prince, P. J.; Williams, J. D.; Lane, R. S.
PY 1989

L11 ANSWER 11 OF 45 CA COPYRIGHT 1994 ACS
AN CA111(15):130280n CA
TI Fluoroplastic immunoaffinity columns for purification of blood proteins
SO U.S., 5 pp.
IN Zimmerman, Theodore S.; Fulcher, Carol A.
PI US 4831118 A 890516
AI US 87-83670 870807
PY 1989

L11 ANSWER 12 OF 45 CA COPYRIGHT 1994 ACS
AN CA111(9):74364d CA
TI A two-stage affinity ultrapurification process for polypeptides such as coagulation **factor VIII:C**
SO Eur. Pat. Appl., 17 pp.
IN Griffith, Michael J.; Neslund, Gerald; Liu, Shu Len
PI EP 286323 A2 881012
AI EP 88-302905 880331
PY 1988

L11 ANSWER 13 OF 45 CA COPYRIGHT 1994 ACS
AN CA111(1):4918p CA
TI Storage of whole blood for up to 24 hours at ambient temperature prior to component **preparation**
SO Vox Sang., 56(3), 145-50
AU Pietersz, R. N. I.; De Korte, D.; Reesink, H. W.; Dekker, W. J. A.; Van den Ende, A.; Loos, J. A.
PY 1989

L11 ANSWER 14 OF 45 CA COPYRIGHT 1994 ACS
AN CA110(20):179379v CA
TI Subcutaneous injection of desmopressin (DDAVP): evaluation of a new, more concentrated **preparation**
SO Haemostasis, 19(1), 38-44
AU Koehler, Michael; Hellstern, P.; Tarrach, H.; Bambauer, R.; Wenzel, E.; Jutzler, G. A.
PY 1989

L11 ANSWER 15 OF 45 CA COPYRIGHT 1994 ACS
AN CA110(18):160275m CA
TI **Preparation** of cryoprecipitate in blood bags
SO Pharmazie, 44(1), 71
AU Uteg, K. H.; Tausendfreund, K.
PY 1989

L11 ANSWER 16 OF 45 CA COPYRIGHT 1994 ACS
AN CA110(13):112360p CA
TI Factor VIII procoagulant protein interacts with phospholipid vesicles via its 80 kDa light chain
SO Thromb. Haemostasis, 60(3), 442-6
AU Kemball-Cook, G.; Edwards, S. J.; Sewerin, K.; Andersson, L. O.; Barrowcliffe, T. W.
PY 1988

L11 ANSWER 17 OF 45 CA COPYRIGHT 1994 ACS
AN CA110(4):29087j CA
TI **Preparation** of **factor VIII:C**

-free blood plasma
SO Ger. Offen., 5 pp.
IN Becker, Udo; Heimburger, Norbert; Braun, Konrad
PI DE 3707213 A1 880915
AI DE 87-3707213 870306
PY 1988

L11 ANSWER 18 OF 45 CA COPYRIGHT 1994 ACS
AN CA109(17):143979f CA
TI High-level inducible expression of heterologous genes using plasmids
encoding a receptor and plasmids containing a gene responsive to the
ligand-receptor complex, and cells containing these plasmids
SO PCT Int. Appl., 35 pp.
IN Kaufman, Randal J.; Israel, David
PI WO 8800975 A1 880211
AI WO 87-US1871 870731
PY 1988

L11 ANSWER 19 OF 45 CA COPYRIGHT 1994 ACS
AN CA109(16):134870m CA
TI Studies on the procurement of blood coagulation factor VIII. In
vitro studies on blood components **prepared** in
half-strength citrate anticoagulant 18 hours after phlebotomy
SO Vox Sang., 55(1), 9-13
AU Griffin, B.; Bell, K.; Prowse, C.
PY 1988

L11 ANSWER 20 OF 45 CA COPYRIGHT 1994 ACS
AN CA108(25):219500v CA
TI Coagulation activities of plasma microparticles
SO Thromb. Res., 50(1), 145-56
AU Howard, M. A.; Coghlan, M.; David, R.; Pfueller, S. L.
PY 1988

L11 ANSWER 21 OF 45 CA COPYRIGHT 1994 ACS
AN CA108(9):70164d CA
TI **Preparation** of recombinant protein complex with human **factor VIII:C** clotting activity for
treatment of bleeding disorder
SO Eur. Pat. Appl., 17 pp.
IN Burke, Rae Lyn; Rasmussen, Mirella Ezban
PI EP 232112 A2 870812
AI EP 87-300695 870127
PY 1987

L11 ANSWER 22 OF 45 CA COPYRIGHT 1994 ACS
AN CA107(12):102499q CA
TI In vitro characterization of various factor VIII concentrates

SO Arzneim.-Forsch., 37(7), 753-6
AU Yoshioka, A.; Shima, M.; Nishino, M.; Yoshikawa, N.; Fukui, H.
PY 1987

L11 ANSWER 23 OF 45 CA COPYRIGHT 1994 ACS
AN CA107(4):28365z CA
TI Deglycosylated human **factor VIII:C**
SO U.S., 13 pp. Cont.-in-part of U.S. 4,495,175.
IN Chavin, Stephen I.; Fay, Philip J.
PI US 4614795 A 860930
AI US 84-570728 840113
PY 1986

L11 ANSWER 24 OF 45 CA COPYRIGHT 1994 ACS
AN CA106(26):219573e CA
TI Separation of antifactor VIII:C antibodies, especially for use in
the blood plasma purification of a type A hemophilic
SO Eur. Pat. Appl., 15 pp.
IN Belattar, Noureddine; Gulino, Danielle; Jozefonvicz, Jacqueline
PI EP 203865 A1 861203
AI EP 86-401115 860527
PY 1986

L11 ANSWER 25 OF 45 CA COPYRIGHT 1994 ACS
AN CA106(24):201672b CA
TI Interactions between derivatives of insoluble polystyrene and human
antibodies to **Factor VIII:C**
SO Polym. Sci. Technol. (Plenum), 34(Polym. Med. 2), 127-37
AU Belattar, N.; Gulino, D.; Jozefonvicz, J.; Sultan, Y.
PY 1986

L11 ANSWER 26 OF 45 CA COPYRIGHT 1994 ACS
AN CA105(16):139598f CA
TI **Preparation** for the treatment of hemophilia A inhibitor patients
SO PCT Int. Appl., 32 pp.
IN Nordfang, Ole; Rasmussen, Mirella Ezban
PI WO 8602838 A1 860522
AI WO 85-DK105 851105
PY 1986

L11 ANSWER 27 OF 45 CA COPYRIGHT 1994 ACS
AN CA104(11):84826a CA
TI **Factor VIII:C** assay standardization
SO Dev. Hematol. Immunol., 13(Plasma Fractionation Blood Transfus.),
217-22
AU Das, P. C.; Thijssen, P. H. M. J.; McShine, R. L.; Sibinga, C. T.

Smit
PY 1985

L11 ANSWER 28 OF 45 CA COPYRIGHT 1994 ACS
AN CA104(5):29838f CA
TI Recombinant **factor VIII-C**
SO Eur. Pat. Appl., 25 pp.
IN Drohan, William Nash; Ricca, George A.; Lee, Sally S. G.
PI EP 157556 A2 851009
AI EP 85-301992 850322
PY 1985

L11 ANSWER 29 OF 45 CA COPYRIGHT 1994 ACS
AN CA103(13):103478m CA
TI Isolation and culture of adrenal medullary endothelial cells producing blood clotting **Factor VIII:C**
SO U. S. Pat. Appl., 36 pp. Avail. NTIS Order No. PAT-APPL-6-672 451.
IN Pollard, H. B.
PI US 672451 A0 850510
AI US 84-672451 841116
PY 1985

L11 ANSWER 30 OF 45 CA COPYRIGHT 1994 ACS
AN CA103(12):92685y CA
TI Isolation of human **factor VIII:C** by **preparative** high-performance size-exclusion chromatography
SO J. Chromatogr., 326, 217-24
AU Herring, Steven W.; Shitanishi, Kenneth T.; Moody, Katherine E.;
Enns, Russel K.
PY 1985

L11 ANSWER 31 OF 45 CA COPYRIGHT 1994 ACS
AN CA103(11):82729b CA
TI Production of factor VIII and related products
SO PCT Int. Appl., 72 pp.
IN Toole, John J., Jr.
PI WO 8501961 A1 850509
AI WO 84-US1641 841012
PY 1985

L11 ANSWER 32 OF 45 CA COPYRIGHT 1994 ACS
AN CA103(10):76114f CA
TI In vitro characterization of the human plasma fraction factor VIII concentrate
SO Pharmazie, 40(4), 270
AU Uteg, K. H.; Tausendfreund, K.; Schoessler, W.
PY 1985

L11 ANSWER 33 OF 45 CA COPYRIGHT 1994 ACS
AN CA103(10):76110b CA

TI Use of segments for the quality control of factor VIII: coagulant
activity of fresh frozen plasma
SO Vox Sang., 48(4), 213-16
AU Ofosu, F. A.; Blajchman, M. A.; Kaegi, A.; Turc, J. M.
PY 1985

L11 ANSWER 34 OF 45 CA COPYRIGHT 1994 ACS
AN CA102(19):164974w CA
TI Dependence of the factor VIII activity on blood groups
SO Pharmazie, 40(1), 57-8
AU Uteg, K. H.; Tausendfreund, K.
PY 1985

L11 ANSWER 35 OF 45 CA COPYRIGHT 1994 ACS
AN CA102(10):84390n CA
TI Factor VIII coagulant polypeptides and monoclonal antibodies to them
SO Eur. Pat. Appl., 46 pp.
IN Zimmerman, Theodore S.; Fulcher, Carol A.
PI EP 123945 A1 841107
AI EP 84-103630 840402
PY 1984

L11 ANSWER 36 OF 45 CA COPYRIGHT 1994 ACS
AN CA101(17):147234s CA
TI Purification of the factor VIII complex
SO Thromb. Res., 35(4), 431-50
AU Thorell, Lars; Blombaeck, Birger
PY 1984

L11 ANSWER 37 OF 45 CA COPYRIGHT 1994 ACS
AN CA101(3):21178h CA
TI Kinetic studies of the activation of factor X by factors IXa and
VIII:C in the absence of thrombin
SO Br. J. Haematol., 57(1), 123-31
AU Neal, Gregory G.; Esnouf, M. Peter
PY 1984

L11 ANSWER 38 OF 45 CA COPYRIGHT 1994 ACS
AN CA100(9):64380q CA
TI Deterioration of **factor VIII:C** in
stored plasma for use in activity curves
SO Lab. Med., 15(1), 40-1
AU Palkuti, Harlene S.
PY 1984

L11 ANSWER 39 OF 45 CA COPYRIGHT 1994 ACS
AN CA100(3):20025y CA
TI Standardization of factor VIII - IV. Establishment of the 3rd
International Standard for **factor VIII:C**

concentrate
SO Thromb. Haemostasis, 50(3), 697-702
AU Barrowcliffe, T. W.; Curtis, A. D.; Thomas, D. P.
PY 1983

L11 ANSWER 40 OF 45 CA COPYRIGHT 1994 ACS
AN CA99(16):128326x CA
TI Blood coagulation **Factor VIII:C**
SO U.S., 6 pp.
IN Johnson, John H.
PI US 4397841 A 830809
AI US 82-392929 820628
PY 1983

L11 ANSWER 41 OF 45 CA COPYRIGHT 1994 ACS
AN CA97(8):60863w CA
TI Control of large-scale plasma thawing for recovery of cryoprecipitate factor VIII
SO Vox Sang., 42(4), 180-9
AU Foster, Peter R.; Dickson, Alan J.; McQuillan, Thomas A.; Dickson, Ida H.; Keddie, Samuel; Watt, John G.
PY 1982

L11 ANSWER 42 OF 45 CA COPYRIGHT 1994 ACS
AN CA96(25):213755u CA
TI Porcine **factor VIII:C prepared** by affinity interaction with von Willebrand factor and heterologous antibodies: sodium dodecyl sulfate polyacrylamide gel analysis
SO Blood, 59(3), 615-24
AU Knutson, Gaylord J.; Fass, David N.
PY 1982

L11 ANSWER 43 OF 45 CA COPYRIGHT 1994 ACS
AN CA93(10):101409r CA
TI In vitro and in vivo characterization of factor VIII **preparations**
SO Vox Sang., 38(2), 68-80
AU Allain, J. P.; Verroust, F.; Soulier, J. P.
PY 1980

L11 ANSWER 44 OF 45 CA COPYRIGHT 1994 ACS
AN CA90(16):127439p CA
TI The properties of factor VIII coagulant activity **prepared** by immunoadsorbent chromatography
SO J. Lab. Clin. Med., 93(1), 40-53
AU Tuddenham, Edward G. D.; Trabold, Norma C.; Collins, John A.; Hoyer, Leon W.
PY 1979

L11 ANSWER 45 OF 45 CA COPYRIGHT 1994 ACS
AN CA89(7):55806k CA
TI Purification of **F.VIII:C** by antigen-antibody chromatography
SO Thromb. Res., 12(4), 667-75
AU Holmberg, L.; Ljung, R.
PY 1978

L12 20 L6 NOT L11

=> d 1-20 an ti so au pi ai py;s freudenberg, w?/au

L12 ANSWER 1 OF 20 CA COPYRIGHT 1994 ACS
AN CA119(22):233771t CA
TI Method for manufacturing chemically virus-inactivated, high purity factor VIII concentrate with an overall yield of 35% feasible for small pool production in developing countries
SO Colloq. INSERM, 227(Biotechnology of Blood Proteins), 103-8
AU Wallevik, Knut; Glavind, Goeren; Hansen, Eva; Ingerslev, Joergen; Joergensen, Jan
PY 1993

L12 ANSWER 2 OF 20 CA COPYRIGHT 1994 ACS
AN CA116(26):262341w CA
TI Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate
SO Vox Sang., 62(1), 1-11
AU Burnouf-Radosevich, M.; Burnouf, T.
PY 1992

L12 ANSWER 3 OF 20 CA COPYRIGHT 1994 ACS
AN CA116(4):27900u CA
TI Ultrapure **plasma** factor VIII produced by anti-F VIIIc immunoaffinity chromatography and solvent/**detergent** viral inactivation. Charaterization of the Method M process and Hemofil M antihemophilic factor (human)
SO Ann. Hematol., 63(3), 131-7
AU Griffith, M.
PY 1991

L12 ANSWER 4 OF 20 CA COPYRIGHT 1994 ACS
AN CA115(24):263169n CA
TI Removal of parvovirus B19 from contaminated factor VIII during fractionation
SO J. Med. Virol., 35(1), 28-31
AU Schwarz, Tino F.; Roggendorf, Michael; Hottentraeger, Barbara;

Stolz, Wilhelm; Schwinn, Horst
PY 1991

L12 ANSWER 5 OF 20 CA COPYRIGHT 1994 ACS
AN CA114(18):171102m CA
TI High-purity factor VIII concentrates produced without using monoclonal antibodies
SO Ric. Clin. Lab., 20(4), 227-37
AU Mannucci, Pier Mannuccio; Gringeri, Alessandro; Cattaneo, Marco
PY 1990

L12 ANSWER 6 OF 20 CA COPYRIGHT 1994 ACS
AN CA114(17):161836q CA
TI von Willebrand factor in lysates of washed canine platelets
SO Am. J. Vet. Res., 52(1), 119-25
AU Parker, Michael T.; Turrentine, Mark A.; Johnson, Gary S.
PY 1991

L12 ANSWER 7 OF 20 CA COPYRIGHT 1994 ACS
AN CA114(15):135521p CA
TI Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates
SO Thromb. Res., 61(3), 285-90
AU Morfini, M.; Mannucci, P. M.; Longo, G.; Cinotti, S.; Messori, A.
PY 1991

L12 ANSWER 8 OF 20 CA COPYRIGHT 1994 ACS
AN CA114(7):58483y CA
TI Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography
SO Eur. Pat. Appl., 11 pp.
IN Bonomo, Richard J.
PI EP 366946 A1 900509
AI EP 89-118199 890930
PY 1990

L12 ANSWER 9 OF 20 CA COPYRIGHT 1994 ACS
AN CA113(12):103341t CA
TI Biochemical and physical properties of a solvent-detergent-treated fibrin glue
SO Vox Sang., 58(2), 77-84
AU Burnouf-Radosevich, Miryana; Burnouf, T.; Huart, J. J.
PY 1990

L12 ANSWER 10 OF 20 CA COPYRIGHT 1994 ACS
AN CA112(3):18399c CA
TI A **plasma Factor VIII:C** concentrate purified by immunoaffinity chromatography
SO Colloq. INSERM, 175(Biotechnol. Proteines Plasma), 263-70

AU Liu, S.; Addiego, J.; Comperts, E.; Kessler, C.; Garanchon, L.;
Neslund, G.; Foster, V.; Berkebile, R.; Courter, S.; et al.
PY 1989

L12 ANSWER 11 OF 20 CA COPYRIGHT 1994 ACS
AN CA106(26):219422e CA
TI Tri(n-butyl) phosphate/**detergent** treatment of licensed therapeutic and experimental blood derivatives
SO Vox Sang., 52(1-2), 53-9
AU Edwards, Carol A.; Piet, Marcel P. J.; Chin, Sing; Horowitz, Bernard
PY 1987

L12 ANSWER 12 OF 20 CA COPYRIGHT 1994 ACS
AN CA104(8):56264x CA
TI Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate **detergent** combinations
SO Transfusion (Philadelphia), 25(6), 516-22
AU Horowitz, B.; Wiebe, M. E.; Lippin, A.; Stryker, M. H.
PY 1985

L12 ANSWER 13 OF 20 CA COPYRIGHT 1994 ACS
AN CA103(7):51852g CA
TI Multimeric analysis of von Willebrand factor in megakaryocytes
SO Thromb. Res., 38(6), 603-10
AU Kupinski, John M.; Miller, Jonathan L.
PY 1985

L12 ANSWER 14 OF 20 CA COPYRIGHT 1994 ACS
AN CA103(5):35829z CA
TI Monoclonal antibodies against the human factor VIII von Willebrand molecule: characterization and potential for screening of von Willebrand patients
SO Dev. Biol. Stand., 57(Monoclonal Antibodies), 69-76
AU Avner, P.; Arnaud, Danielle; Sultan, Yvette; Maisonneuve, Pascale; Jeanneau, Christine
PY 1984

L12 ANSWER 15 OF 20 CA COPYRIGHT 1994 ACS
AN CA102(21):183123j CA
TI Endothelial cell synthesis of von Willebrand antigen II, von Willebrand factor, and von Willebrand factor/von Willebrand antigen II complex
SO J. Clin. Invest., 75(4), 1089-95
AU McCarroll, David R.; Levin, Eugene G.; Montgomery, Robert R.

PY 1985

L12 ANSWER 16 OF 20 CA COPYRIGHT 1994 ACS
AN CA102(16):137785d CA
TI Undenatured virus-free biologically active protein derivatives
SO Eur. Pat. Appl., 34 pp.
IN Neurath, Alexander Robert; Horowitz, Bernhard
PI EP 131740 A2 850123
AI EP 84-106557 840608
PY 1985

L12 ANSWER 17 OF 20 CA COPYRIGHT 1994 ACS
AN CA102(13):110554r CA
TI Cleavage of human von Willebrand factor by platelet calcium-activated protease
SO Blood, 65(2), 352-6
AU Kunicki, Thomas J.; Montgomery, Robert R.; Schullek, John
PY 1985

L12 ANSWER 18 OF 20 CA COPYRIGHT 1994 ACS
AN CA102(4):32228w CA
TI Sterilized **plasma** and **plasma** derivatives
SO U.S., 8 pp.
IN Prince, Alfred M.
PI US 4481189 A 841106
AI US 82-368250 820414
PY 1984

L12 ANSWER 19 OF 20 CA COPYRIGHT 1994 ACS
AN CA94(7):43681f CA
TI Reconstitution of liposomes bearing platelet receptors for human von Willebrand factor
SO Biochem. Biophys. Res. Commun., 97(1), 133-8
AU Sie, P.; Gillois, M.; Boneu, B.; Chap, H.; Bierme, R.; Douste-Blazy, L.
PY 1980

L12 ANSWER 20 OF 20 CA COPYRIGHT 1994 ACS
AN CA77(19):124371f CA
TI Antihemophilic factor. Separation of an active fragment following dissociation by salts or detergents
SO Thromb. Diath. Haemorrh., 27(3), 502-15
AU Owen, W. G.; Wagner, Robert H.
PY 1972

L13 15 FREUDENBERG, W?/AU

=> dis his

```
      (FILE 'HOME' ENTERED AT 13:21:56 ON 03 JUN 94)
                  SET PAGELENGTH SCROLL

      FILE 'REGISTRY' ENTERED AT 13:23:09 ON 03 JUN 94
                  E FACTOR VIII/CN
L1              3 S E3
                  E F VIII C/CN

      FILE 'CA' ENTERED AT 13:24:01 ON 03 JUN 94
L2           3786 S (L1 OR ((FACTOR OR F)(W)VIII(W)C)/IA)
L3             36 S L2 AND (ORGANIC POLYMER OR DETERGENT)/IA
L4             23 S L3 AND PLASMA/IA
L5              3 S L4 AND (STABIL? OR STABL? OR BUFFER?)/IA
L6             20 S L4 NOT L5
L7              0 S L6 AND (AMINO ACID OR (ARGININE AND GLYCINE)
OR (ARG AN
L8              0 S L6 AND CARBOHYDRATE?/IA
L9            200 S (((FACTOR OR F)(W)VIII(W)C)/IA)
L10            46 S L9 AND (PREPAR? OR PREPN)/IA
L11            45 S L10 NOT L5
L12            20 S L6 NOT L11
L13            15 S FREUDENBERG, W?/AU

=> s l13 not (l5 or l6 or l11)
L14           15 L13 NOT (L5 OR L6 OR L11)

=> s l14 and l2
L15            1 L14 AND L2

=> d .mh;s l14 not l15

L15  ANSWER 1 OF 1  CA  COPYRIGHT 1994 ACS
TI   Stabilization of blood coagulation factor VIII with amino
acids
SO   Eur. Pat. Appl., 6 pp.
IN   Freudenberg, Wilfried
PI   EP 508194 A1  921014
AI   EP 92-104944  920321
PY   1992
AN   CA117(26):258195e  CA
AB   Stabilizers for blood coagulation factor VIIIc in conc. aq.
soln.,
     comprise an amino acid and, optionally, an org. polymer or a
     nonionic surfactant. An aq. soln. of 1% sucrose, 0.M
glycine, 0.14M
     arginine, 0.1M NaCl, and 0.05% Tween-80, used at a 1:1 vol.
ratio,
     stabilized a coagulation factor VIIIc eluate (1,860
IU/mg/protein),
     purified by immune-affinity chromatog.
```

L16 14 L14 NOT L15

=> d 1-14 an ti so au ai pi py

L16 ANSWER 1 OF 14 CA COPYRIGHT 1994 ACS
AN CA120(5):50032d CA
TI Thermal inactivation of viruses in protein preparations
SO Eur. Pat. Appl., 8 pp.
IN Keuper, Hermann; Matzmorr, Walter; Freudenberg, Wilfried
AI EP 93-106848 930428
PI EP 571771 A2 931201
PY 1993

L16 ANSWER 2 OF 14 CA COPYRIGHT 1994 ACS
AN CA116(7):54080h CA
TI Electron-transferring flavoproteins from glycine-metabolizing
anaerobic bacteria
SO Flavins Flavoproteins Proc. Int. Symp., 10th, Meeting Date 1990,
611-14. Edited by: Curti, Bruno; Ronchi, Severino; Zanetti, Giuliana. de Gruyter: Berlin, Fed. Rep. Ger.
AU Dietrichs, D.; Meyer, M.; Uhde, A.; Freudenberg, W.; Andreesen, J.
R.
PY 1991

L16 ANSWER 3 OF 14 CA COPYRIGHT 1994 ACS
AN CA114(19):184811s CA
TI Preparation of granular sodium acetate trihydrate
SO Ger. (East), 3 pp.
IN Freudenberg, Werner; Heidrich, Matthias; Hoenisch, Dietrich; Kniest,
Steffen; Wegner, Joachim; Boeber, Reinhard; Peter, Siegfried; Wand,
Bernhard
AI DD 89-333833 891024
PI DD 285591 A5 901219
PY 1990

L16 ANSWER 4 OF 14 CA COPYRIGHT 1994 ACS
AN CA112(20):181861f CA
TI Alkali metal carboxylate granules of high bulk density and constant
particle size
SO Ger. (East), 3 pp.
IN Boeber, Reinhard; Peter, Siegfried; Prahl, Wolfgang; Litzke, Ursula;
Wand, Bernhard; Kniest, Steffen; Freudenberg, Werner; Wegner,
Joachim
AI DD 88-317420 880701
PI DD 273627 A1 891122

PY 1989

L16 ANSWER 5 OF 14 CA COPYRIGHT 1994 ACS
AN CA112(19):175285e CA
TI Involvement of a selenoprotein in glycine, sarcosine, and betaine
reduction by Eubacterium acidaminophilum
SO Selenium Biol. Med., [Proc. Int. Symp.], 4th, Meeting Date 1988,
25-8. Edited by: Wendel, Albrecht. Springer: Berlin, Fed. Rep.
Ger.
AU Freudenberg, W.; Hormann, K.; Rieth, M.; Andreesen, J. R.
PY 1989

L16 ANSWER 6 OF 14 CA COPYRIGHT 1994 ACS
AN CA111(11):93621b CA
TI Immunocytochemical localization of proteins P1, P2, P3 of glycine
decarboxylase and of the selenoprotein PA of glycine reductase, all
involved in anaerobic glycine metabolism of Eubacterium acidaminophilum
SO Arch. Microbiol., 152(2), 182-8
AU Freudenberg, W.; Mayer, F.; Andreesen, J. R.
PY 1989

L16 ANSWER 7 OF 14 CA COPYRIGHT 1994 ACS
AN CA110(21):188299w CA
TI Purification and partial characterization of the glycine decarboxylase multienzyme complex from Eubacterium acidaminophilum
SO J. Bacteriol., 171(4), 2209-15
AU Freudenberg, Wilfried; Andreesen, Jan Remmer
PY 1989

L16 ANSWER 8 OF 14 CA COPYRIGHT 1994 ACS
AN CA110(19):168932u CA
TI Isolation of an atypically small lipoamide dehydrogenase involved in
the glycine decarboxylase complex from Eubacterium acidaminophilum
SO J. Bacteriol., 171(3), 1346-54
AU Freudenberg, Wilfried; Dietrichs, Daniel; Lebertz, Herbert; Andreesen, Jan Remmer
PY 1989

L16 ANSWER 9 OF 14 CA COPYRIGHT 1994 ACS
AN CA109(17):145983b CA
TI Eubacterium acidaminophilum sp. nov., a versatile amino acid-degrading anaerobe producing or utilizing hydrogen or formate.
Description and enzymic studies

SO Arch. Microbiol., 150(3), 254-66
AU Zindel, U.; Freudenberg, W.; Rieth, M.; Andreesen, J. R.; Schnell,
J.; Widdel, F.
PY 1988

L16 ANSWER 10 OF 14 CA COPYRIGHT 1994 ACS
AN CA109(17):145043v CA
TI Nicotine dehydrogenase from Arthrobacter oxidans: a molybdenum-containing hydroxylase
SO FEMS Microbiol. Lett., 52(1-2), 13-17
AU Freudenberg, Wilfried; Koenig, Kerstin; Andreesen, Jan Remmer
PY 1988

L16 ANSWER 11 OF 14 CA COPYRIGHT 1994 ACS
AN CA107(9):76126u CA
TI Improvement of the useful properties of a biolipid extract
SO Ger. (East), 4 pp.
IN Freudenberg, Werner; Poetzsch, Armin; Gedecke, Guenther
AI DD 85-275442 850423
PI DD 236551 A1 860611
PY 1986

L16 ANSWER 12 OF 14 CA COPYRIGHT 1994 ACS
AN CA104(14):111813c CA
TI Synthetic wax
SO Ger. (East), 3 pp.
IN Freudenberg, Werner; Poetzsch, Armin
AI DD 84-264847 840702
PI DD 225422 A1 850731
PY 1985

L16 ANSWER 13 OF 14 CA COPYRIGHT 1994 ACS
AN CA96(16):128963r CA
TI Catalyst and methods for afterburning of waste products from paraffin oxidation
SO Ger. (East), 8 pp.
IN Freudenberg, Werner; Straube, Joachim
AI DD 80-221107 800515
PI DD 150600 Z 810909
PY 1981

L16 ANSWER 14 OF 14 CA COPYRIGHT 1994 ACS
AN CA95(7):61517g CA
TI Sodium acetate trihydrate
SO Ger. (East), 5 pp.
IN Freudenberg, Werner; Iltzsche, Gerhard; Kroeber, Erhard; Schmidt,
Rudi
AI DD 78-209138 781117
PI DD 145855 810114
PY 1981

```
=> fil .biotech
FILE 'BIOSIS' ENTERED AT 13:30:51 ON 03 JUN 94
COPYRIGHT (C) 1994 BIOSIS(R)

FILE 'MEDLINE' ENTERED AT 13:30:51 ON 03 JUN 94

FILE 'EMBASE' ENTERED AT 13:30:51 ON 03 JUN 94
COPYRIGHT (C) 1994 Elsevier Science B.V.  All rights reserved.

=> s (factor or f)(W)viii(w)c
FILE 'BIOSIS'
        306697 FACTOR
        106685 F
         11867 VIII
        561641 C
L17        441 (FACTOR OR F)(W)VIII(W)C

FILE 'MEDLINE'
        238659 FACTOR
         62555 F
         13095 VIII
        368536 C
L18        383 (FACTOR OR F)(W)VIII(W)C

FILE 'EMBASE'
        265740 FACTOR
         58205 F
          9726 VIII
        369835 C
L19        181 (FACTOR OR F)(W)VIII(W)C

TOTAL FOR ALL FILES
L20       1005 (FACTOR OR F)(W) VIII(W) C

=> s l20 and freudenberg w?/au
FILE 'BIOSIS'
             7 FREUDENBERG W?/AU
L21          0 L17 AND FREUDENBERG W?/AU

FILE 'MEDLINE'
             2 FREUDENBERG W?/AU
L22          0 L18 AND FREUDENBERG W?/AU

FILE 'EMBASE'
             3 FREUDENBERG W?/AU
L23          0 L19 AND FREUDENBERG W?/AU

TOTAL FOR ALL FILES
L24          0 L20 AND FREUDENBERG W?/AU

=> s l20 and (organic polymer or detergent)
FILE 'BIOSIS'
```

```
         79828 ORGANIC
         14764 POLYMER
            54 ORGANIC POLYMER
                 (ORGANIC(W)POLYMER)
         18023 DETERGENT
L25          4 L17 AND (ORGANIC POLYMER OR DETERGENT)

FILE 'MEDLINE'
         36083 "ORGANIC"
          8110 "POLYMER"
            19 ORGANIC POLYMER
                 ("ORGANIC"(W)"POLYMER")
         12405 DETERGENT
L26          5 L18 AND (ORGANIC POLYMER OR DETERGENT)

FILE 'EMBASE'
         42290 "ORGANIC"
         10914 "POLYMER"
            36 ORGANIC POLYMER
                 ("ORGANIC"(W)"POLYMER")
         11643 DETERGENT
L27          1 L19 AND (ORGANIC POLYMER OR DETERGENT)

TOTAL FOR ALL FILES
L28         10 L20 AND (ORGANIC POLYMER OR DETERGENT)

=> dup rem l28
PROCESSING COMPLETED FOR L28
L29          5 DUP REM L28 (5 DUPLICATES REMOVED)

=> d an ti so au ab 1-5

L29  ANSWER 1 OF 5  BIOSIS  COPYRIGHT 1994 BIOSIS      DUPLICATE
1
AN  93:114344  BIOSIS
TI  VIRUS INACTIVATION OF FRESH FROZEN PLASMA BY A SOLVENT
    DETERGENT PROCEDURE BIOLOGICAL RESULTS.
SO  VOX SANG 63 (4). 1992.  251-256. CODEN: VOSAAD ISSN:
0042-9007
AU  PIQUET Y; JANVIER G; SELOSSE P; DOUTREMEPUICH C; JOUNEAU J;
NICOLLE
    G; PLATEL D; VEZON G
AB  In order to increase the safety of blood products, we have
developed
    a procedure for the virus inactivation of fresh frozen
plasma.
    Several batches have been prepared and with the first 10
batches,
    each of them composed of 60 litres of plasma, we have
determined a
    set of biological parameters. Virus inactivation was
realised using
    TnBP (1%) and Octoxynol 9 (1%). After their elimination with
castor
```

oil using chromatography on insolubilized C18 resin, glycine was added and the pH of the plasma was adjusted to 7.4. Plastic bags were aseptically filled with a mean volume of 200 ml of plasma. The mean levels of coagulation factors were all over 0.7 U/ml and their recovery from initial plasma was nearly the same as total protein except for **factor VIII:C**. The net loss in **factor VIII:C** was 16%, when including the dilution of plasma. In vivo and in vitro tests demonstrated that in the final product there were no activated factors. As in fresh frozen plasma, the protein concentrations was over 50 g/l and the potassium level lower than 5 mmol/l. According to these results, virus-inactivated plasma has the same qualities of fresh frozen plasma and could now replace it.

L29 ANSWER 2 OF 5 BIOSIS COPYRIGHT 1994 BIOSIS DUPLICATE 2
AN 92:214745 BIOSIS
TI CLINICAL AND BIOLOGICAL EVALUATION IN VON WILLEBRAND'S DISEASE OF A VON WILLEBRAND FACTOR CONCENTRATE WITH LOW FACTOR VIII ACTIVITY.
SO BR J HAEMATOL 80 (2). 1992. 214-221. CODEN: BJHEAL ISSN: 0007-1048
AU GOUDEMAND J; MAZURIER C; MAREY A; CARON C; COUPEZ B; MIZON P; GOUDEMAND M
AB This study was carried out to assess the clinical efficacy in von Willebrand's disease (vWD) of a new, very high purity (VHP), solvent/**detergent** (SD)-treated, vWF concentrate (VHP Human von Willebrand Factor Concentrate, Biotransfusion) characterized by a high specific ristocetin cofactor (vWF:RCo) activity and a low factor VIII (FVIII) coagulant activity (FVIII:C). Nine patients (four type I, one type IIA, one type IIB, one type IIC, one type III and one acquired type II) were infused on 13 occasions including a pharmacokinetic study. Satisfactory haemostasis was achieved in all cases, including the treatment of spontaneous haemorrhages and the prevention of bleeding following surgery. The bleeding time was

corrected for 6-12 h in 6/9 patients and shortened in the others.
Furthermore, it was shown that the plasma vWF multimeric pattern of types II and III patients was greatly improved. When measured in eight patients 1 h after infusion, the vWF:RCo recovery was 77.3 (.+-. 10.7)% while the **F VIII:C** recovery was strikingly higher (876 .+-. 906%). This high recovery is likely related to the predominant 'pseudo-synthesis' of FVIII following the restoration of normal vWF levels. Maximum levels of FVIII:C occurred 6-12 h after the first infusion and normal levels of FVIII:C were maintained throughout the treatments with a dosage of 26-39 IU/kg vWF:RCo and only 0.2-5 IU/kg FVIII:C. The half-lives of the vWF-related parameters determined in a type III vWD patient were 20.6 h for vWF antigen, 17.8 h for vWF:RCo, 14 h for the high molecular weight multimers of vWF, 55.3 h for FVIII:Ag and 74 h for FVIII:C. In conclusion, it does not appear necessary that vWF concentrations intended for the treatment of vWD should contain FVIII in addition to vWF to be clinically effective in most patients.

L29 ANSWER 3 OF 5 MEDLINE 1994
AN 92031935 MEDLINE
TI Ultrapure plasma factor VIII produced by anti-**F VIII c** immunoaffinity chromatography and solvent/**detergent** viral inactivation. Characterization of the Method M process and Hemofil M antihemophilic factor (human).
SO Ann Hematol, (1991 Sep) 63 (3) 131-7. Ref: 13
Journal code: A2P. ISSN: 0939-5555.
AU Griffith M

L29 ANSWER 4 OF 5 BIOSIS COPYRIGHT 1994 BIOSIS DUPLICATE 3
AN 90:86697 BIOSIS
TI PROGRESS IN PURIFICATION OF VIRUS-INACTIVATED FACTOR VIII CONCENTRATES THREE GENERATIONS OF SOLVENT-**DETERGENT** TREATED PLASMA DERIVATIVES.
SO ARZNEIM-FORSCH 39 (10). 1989. 1302-1305. CODEN: ARZNAD ISSN: 0004-4172
AU SCHWINN H; SMITH A; WOLTER D
AB A production process of a newly developed highly purified and virus-inactivated Factor (F) VIII-concentrate (Octa V.I. and Octavi)

is presented. Taking advantage of a selective resin matrix and the solvent/**detergent** procedure for virus inactivation - known not to denaturate proteins - a product of a specific activity .gtoreq. 100 IU F VIII/mg could be developed in the final container without the use of an immuno-affinity adsorption step. The main steps of the procedure are; Pooled cryoprecipitate is extracted, the extract is cleared from fibrinogen at + 10.degree. C and virus-inactivated at + 28.degree. C after addition of tributyl-phosphate (TNBP) and **detergent**. Thereafter the extract is brought in contact to a F VIII-selective anion exchange resin using a chromatographic column. TnBP and the **detergent** are removed by an extensive washing process and the F VIII-activity is concentrated in a fraction, ready for filling, by means of a cascade of washing- and elution-buffers. The product is free from coagulable protein and gamma-globulins. The F VIIIC: Ag/**F VIII:C**-ratio is about unity, suggesting the F VIII-molecule remained in its native state. The development of highly purified F VIII concentrate is based on two previous products of lesser purity (spec. activity of about 1 and 10 IU/mg). The evolution is shown by a comparison of detailed analytical data.

L29 ANSWER 5 OF 5 BIOSIS COPYRIGHT 1994 BIOSIS DUPLICATE 4
AN 90:816 BIOSIS
TI COMPARISON OF THE IN-VITRO CHARACTERISTICS OF VON WILLEBRAND FACTOR IN BRITISH AND COMMERCIAL FACTOR VIII CONCENTRATES.
SO BR J HAEMATOL 73 (1). 1989. 100-104. CODEN: BJHEAL ISSN: 0007-1048
AU LAWRIE A S; HARRISON P; ARMSTRONG A L; WILBOURN B R; DALTON R G; SAVIDGE G F
AB Qualitative/quantitative analysis of von Willebrand factor antigen (vWf:Ag) in either heat or solvent/**detergent** treated factor VIII concentrates, used for haemophilia replacement therapy, was undertaken to assess their suitability for the treatment of vWD. For the first time immunoaffinity purified vWf:Ag (Monoclate by-product) was also evaluated by in vitro assessment. Potencies of vWF:Ag varied

considerably but were consistently higher (28.9-420.5 iu/ml) than
factor VIII:C (one-stage) activity
(8.13-42.44 iu/ml). The functional activity of vWf was assessed by
either Ristocetin Cofactor (vWf:Rco) or collagen binding methods
(vWf:CBA) with typical vWf:RCo/vWf:Ag ratios from 0.08 to 0.94.
Multimeric analysis confirmed that in vitro biological activity was
dependent on the presence of the high molecular weight forms of
vWf:Ag. A significant correlation (r = 0.95) between vWf:RCo activity
and collagen binding was observed in all of the concentrates with the
exception of the immunopurified product. The data suggest that
either NHS 8Y (mean vWfRCo/vWf:Ag = 0.94), Haemate P (mean
vWf:RCo/vWf:Ag = 0.69) and high purity Octapharma V.I (vWf:RCo/vWf:Ag
= 0.82) which contain medium/high MW vWf:Ag multimers are likely to
be most cost-effective in the treatment of symptomatic severe vWD
patients than other currently available concentrates.

```
=> s l20 and (amino acid or (arginine and glycine) or (arg and
gly))
FILE 'BIOSIS'
        271052 AMINO
        669958 ACID
        147922 AMINO ACID
                 (AMINO(W)ACID)
         32637 ARGININE
         38791 GLYCINE
         10715 ARG
         11142 GLY
L30          6 L17 AND (AMINO ACID OR (ARGININE AND GLYCINE) OR
(ARG AND
               GLY))

FILE 'MEDLINE'
        249957 "AMINO"
        635373 "ACID"
        163334 AMINO ACID
                 ("AMINO"(W)"ACID")
         27763 ARGININE
         21738 GLYCINE
         10040 ARG
         10315 GLY
L31         11 L18 AND (AMINO ACID OR (ARGININE AND GLYCINE) OR
(ARG AND
```

```
                GLY))

FILE 'EMBASE'
         144219 "AMINO"
         690306 "ACID"
          89376 AMINO ACID
                  ("AMINO"(W)"ACID")
          22940 ARGININE
          17807 GLYCINE
           7827 ARG
           8178 GLY
L32           2 L19 AND (AMINO ACID OR (ARGININE AND GLYCINE) OR
(ARG AND
                GLY))

TOTAL FOR ALL FILES
L33          19 L20 AND (AMINO ACID OR (ARGININE AND GLYCINE) OR
(ARG AND
                GLY))

=> s l33 and carbohydrate
FILE 'BIOSIS'
          51920 CARBOHYDRATE
L34           0 L30 AND CARBOHYDRATE

FILE 'MEDLINE'
          39683 CARBOHYDRATE
L35           0 L31 AND CARBOHYDRATE

FILE 'EMBASE'
          31338 CARBOHYDRATE
L36           0 L32 AND CARBOHYDRATE

TOTAL FOR ALL FILES
L37           0 L33 AND CARBOHYDRATE

=> dup rem l33
PROCESSING COMPLETED FOR L33
L38          12 DUP REM L33 (7 DUPLICATES REMOVED)

=> d an ti so au 1-12

L38  ANSWER 1 OF 12  MEDLINE  1994
AN   91069319     MEDLINE
TI   [Chemistry and clinical significance of human plasma
proteins].
     Chemie und klinische Bedeutung der Human-Plasmaproteine.
SO   Behring Inst Mitt, (1990 Oct) (86) 1-66.  Ref: 336
     Journal code: 9KI. ISSN: 0301-0457.
AU   Haupt H

L38  ANSWER 2 OF 12  BIOSIS  COPYRIGHT 1994 BIOSIS     DUPLICATE
1
```

AN 89:178216 BIOSIS
TI IDENTIFICATION OF A FACTOR VIII EPITOPE RECOGNIZED BY A HUMAN HEMOPHILIC INHIBITOR.
SO BLOOD 73 (2). 1989. 497-499. CODEN: BLOOAW ISSN: 0006-4971
AU LUBAHN B C; WARE J; STAFFORD D W; REISNER H M

L38 ANSWER 3 OF 12 BIOSIS COPYRIGHT 1994 BIOSIS DUPLICATE 2
AN 89:220165 BIOSIS
TI A MONOCLONAL IMMUNOGLOBULIN A KAPPA FACTOR VII C INHIBITOR ASSOCIATED
WITH PRIMARY AMYLOIDOSIS IDENTIFICATION AND CHARACTERIZATION.
SO J LAB CLIN MED 113 (3). 1989. 269-277. CODEN: JLCMAK ISSN: 0022-2143
AU GLUECK H I; COOTS M C; BENSON M; DWULET F E; HURTUBISE P E

L38 ANSWER 4 OF 12 MEDLINE 1994
AN 88309004 MEDLINE
TI Synthesis of biologically active deletion mutants of human **factor VIII:C.**
SO Behring Inst Mitt, (1988 Apr) (82) 16-25.
Journal code: 9KI. ISSN: 0301-0457.
AU Langner KD; Bird RE; McCandliss R; Huber B; Amann E; Zettlmeissl G;
Kupper HA

L38 ANSWER 5 OF 12 MEDLINE 1994
AN 86304432 MEDLINE
TI The functional domains of coagulation **factor VIII :C.**
SO J Biol Chem, (1986 Sep 25) 261 (27) 12574-8.
Journal code: HIV. ISSN: 0021-9258.
AU Burke RL; Pachl C; Quiroga M; Rosenberg S; Haigwood N; Nordfang O;
Ezban M

L38 ANSWER 6 OF 12 MEDLINE 1994
AN 86225810 MEDLINE
TI Disseminated intravascular coagulation following Echis carinatus
venom in dogs: effects of a synthetic thrombin inhibitor.
SO J Lab Clin Med, (1986 Jun) 107 (6) 488-97.
Journal code: IVR. ISSN: 0022-2143.
AU Schaeffer RC Jr; Briston C; Chilton SM; Carlson RW

L38 ANSWER 7 OF 12 MEDLINE 1994
AN 87176513 MEDLINE
TI Desmopressin (DDAVP) for treatment of disorders of hemostasis.
SO Prog Hemost Thromb, (1986) 8 19-45. Ref: 103
Journal code: Q1B. ISSN: 0362-6350.
AU Mannucci PM

L38 ANSWER 8 OF 12 BIOSIS COPYRIGHT 1994 BIOSIS DUPLICATE 3
AN 86:142385 BIOSIS
TI CHARACTERIZATION OF THE POLYPEPTIDE COMPOSITION OF HUMAN **FACTOR-VIII C** AND THE NUCLEOTIDE SEQUENCE AND EXPRESSION OF THE HUMAN KIDNEY COMPLEMENTARY DNA.
SO DNA (N Y) 4 (5). 1985. 333-350. CODEN: DNAADR ISSN: 0198-0238
AU TRUETT M A; BLACHER R; BURKE R L; CAPUT D; CHU C; DINA D; HARTOG K; KUO C H; MASIARZ F R; ET AL

L38 ANSWER 9 OF 12 BIOSIS COPYRIGHT 1994 BIOSIS DUPLICATE 4
AN 84:320514 BIOSIS
TI STABILIZATION OF THROMBIN ACTIVATED PORCINE **FACTOR-VIII C** BY FACTOR-IXA AND PHOSPHO LIPID.
SO BLOOD 63 (6). 1984. 1303-1308. CODEN: BLOOAW ISSN: 0006-4971
AU LOLLAR P; KNUTSON G J; FASS D N

L38 ANSWER 10 OF 12 BIOSIS COPYRIGHT 1994 BIOSIS DUPLICATE 5
AN 85:230093 BIOSIS
TI STRUCTURE-FUNCTION RELATIONSHIPS OF HUMAN FACTOR-VIII COMPLEX STUDIED BY THIOREDOXIN DEPENDENT DISULFIDE REDUCTION.
SO THROMB RES 35 (6). 1984. 637-652. CODEN: THBRAA ISSN: 0049-3848
AU HESSEL B; JORNVALL H; THORELL L; SODERMAN S; LARSSON U; EGBERG N; BLOMBACK B; HOLMGREN A

L38 ANSWER 11 OF 12 MEDLINE 1994
AN 85021377 MEDLINE
TI Inhibition of activated porcine factor IX by dansyl-glutamyl-glycyl-arginyl-chloromethylketone.
SO Arch Biochem Biophys, (1984 Sep) 233 (2) 438-46. Journal code: 6SK. ISSN: 0003-9861.
AU Lollar P; Fass DN

L38 ANSWER 12 OF 12 BIOSIS COPYRIGHT 1994 BIOSIS
AN 84:76926 BIOSIS
TI THE MOLECULAR STRUCTURE OF HUMAN **FACTOR-VIII C**.
SO 9TH INTERNATIONAL CONGRESS ON THROMBOSIS AND HEMOSTASIS, JULY 4-8, 1983. THROMB HEMOSTASIS 50 (1). 1983. 262. CODEN: THHADQ ISSN: 0340-6245
AU KUO G; CRAINE B; MASIARZ F; RALL L; TRUETT M; VALENZUELA P; NORDFANG O; EZBAN M

```
=> dis his l20-

     (FILE 'BIOSIS, MEDLINE, EMBASE' ENTERED AT 13:30:51 ON 03
JUN 94)
     TOTAL FOR ALL FILES
L20         1005 S (FACTOR OR F)(W)VIII(W)C
     FILE 'BIOSIS'
L21            0 S L20 AND FREUDENBERG W?/AU
     FILE 'MEDLINE'
L22            0 S L20 AND FREUDENBERG W?/AU
     FILE 'EMBASE'
L23            0 S L20 AND FREUDENBERG W?/AU
     TOTAL FOR ALL FILES
L24            0 S L20 AND FREUDENBERG W?/AU
     FILE 'BIOSIS'
L25            4 S L20 AND (ORGANIC POLYMER OR DETERGENT)
     FILE 'MEDLINE'
L26            5 S L20 AND (ORGANIC POLYMER OR DETERGENT)
     FILE 'EMBASE'
L27            1 S L20 AND (ORGANIC POLYMER OR DETERGENT)
     TOTAL FOR ALL FILES
L28           10 S L20 AND (ORGANIC POLYMER OR DETERGENT)
L29            5 DUP REM L28 (5 DUPLICATES REMOVED)
     FILE 'BIOSIS'
L30            6 S L20 AND (AMINO ACID OR (ARGININE AND GLYCINE)
OR (ARG A
     FILE 'MEDLINE'
L31           11 S L20 AND (AMINO ACID OR (ARGININE AND GLYCINE)
OR (ARG A
     FILE 'EMBASE'
L32            2 S L20 AND (AMINO ACID OR (ARGININE AND GLYCINE)
OR (ARG A
     TOTAL FOR ALL FILES
L33           19 S L20 AND (AMINO ACID OR (ARGININE AND GLYCINE)
OR (ARG A
     FILE 'BIOSIS'
L34            0 S L33 AND CARBOHYDRATE
     FILE 'MEDLINE'
L35            0 S L33 AND CARBOHYDRATE
     FILE 'EMBASE'
L36            0 S L33 AND CARBOHYDRATE
     TOTAL FOR ALL FILES
L37            0 S L33 AND CARBOHYDRATE
L38           12 DUP REM L33 (7 DUPLICATES REMOVED)

=> s l20 and prepar?
FILE 'BIOSIS'
        259218 PREPAR?
L39          49 L17 AND PREPAR?

FILE 'MEDLINE'
        228848 PREPAR?
```

```
L40          48 L18 AND PREPAR?

FILE 'EMBASE'
        204984 PREPAR?
L41          28 L19 AND PREPAR?

TOTAL FOR ALL FILES
L42         125 L20 AND PREPAR?

=> s l42 and (stabil? or stabl?)
FILE 'BIOSIS'
          98853 STABIL?
          95904 STABL?
L43           9 L39 AND (STABIL? OR STABL?)

FILE 'MEDLINE'
          83470 STABIL?
          75925 STABL?
L44           8 L40 AND (STABIL? OR STABL?)

FILE 'EMBASE'
          74073 STABIL?
          70605 STABL?
L45           5 L41 AND (STABIL? OR STABL?)

TOTAL FOR ALL FILES
L46          22 L42 AND (STABIL? OR STABL?)

=> s l46 and coagul?
FILE 'BIOSIS'
          39077 COAGUL?
L47           1 L43 AND COAGUL?

FILE 'MEDLINE'
          59432 COAGUL?
L48           1 L44 AND COAGUL?

FILE 'EMBASE'
          27947 COAGUL?
L49           0 L45 AND COAGUL?

TOTAL FOR ALL FILES
L50           2 L46 AND COAGUL?

=> dup rem l50
PROCESSING COMPLETED FOR L50
L51            1 DUP REM L50 (1 DUPLICATE REMOVED)

=> d an ti so au ab

L51  ANSWER 1 OF 1  BIOSIS  COPYRIGHT 1994 BIOSIS      DUPLICATE
1
AN  86:139204  BIOSIS
```

TI DEGRADATION OF FACTOR-VIII **COAGULANT** ANTIGEN BY PROTEOLYTIC ENZYMES.

SO BR J HAEMATOL 61 (3). 1985. 477-486. CODEN: BJHEAL ISSN: 0007-1048

AU RICK M E; POPOVSKY M A; KRIZEK D M

AB The factors responsible for the lability for factor VIII **coagulant** activity (VIII:C) and factor VIII **coagulant** antigen (VIII:CAg) are poorly understood. In this study the VIII:C and VIII:CAg are studied after incubation with plasmin, trypsin or .alpha.-chymotrypsin. Both isolated human VIII:CAg and VIII:CAg associated with factor VIII-related antigen (VIII R:Ag) are evaluated. The antigenic sites of the VIII:CAg are somewhat more **stable** to the action of these enzymes than the functional activity, although both follow a generally parallel degradation. A biphasic decay curve is seen in the initial time points. No **stabilization** of the functional or antigenic reactivity is observed in the presence of the VIII R:Ag. Lower concentrations of each enzyme cause an initial rise in the **factor VIII:C** in the presence of VIII R:Ag, but not in the isolated VIII:CAg. Higher concentrations of .alpha.-chymotrypsin cause activation of VIII:C and a slight decrease in the VIII:CAg values in both **preparations**. These enzymes may play a modulating role in the **coagulation** cascade through the activation and degradation of VIII:C and VIII:CAg.